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Abstract
Rationale: Bronchoscopic lung volume reductionwith Zephyr Valves
improves lung function, exercise tolerance, and quality of life of patients
with hyperinflated emphysema and little to no collateral ventilation.
Objectives: Post hoc analysis of patient-reported outcomes (PROs),
including multidimensional measures of dyspnea, activity, and
quality of life, in the LIBERATE (Lung Function Improvement after
Bronchoscopic LungVolume Reductionwith Pulmonx Endobronchial
Valves used in Treatment of Emphysema) study are reported.
Methods: A total of 190 patients with severe heterogeneous
emphysema and little to no collateral ventilation in the target
lobe were randomized 2:1 to the Zephyr Valve or standard
of care. Changes in PROs at 12 months in the two groups
were compared: dyspnea with the Transitional Dyspnea
Index (TDI), focal score; the Chronic Obstructive Pulmonary
Disease Assessment Test (CAT; breathlessness on hill/stairs);
Borg; the EXAcerbations of Chronic pulmonary disease
Tool–PRO, dyspnea domain; activity with the TDI,
magnitude of task/effort/functional impairment, CAT
(limited activities), and the St. George’s Respiratory
Questionnaire (SGRQ), activity domain; and psychosocial status with
the SGRQ, impacts domain, and CAT (confidence and energy).
Results: At 12 months, patients using the Zephyr Valve achieved
statistically significant and clinically meaningful improvements
in the SGRQ; CAT; and the TDI, focal score, compared with
standard of care. Improvements in the SGRQ were driven by
the impacts and activity domains (P, 0.05 and P, 0.001,
respectively). Reduction in CAT was through improvements in
breathlessness (P, 0.05), energy level (P, 0.05), activities
(P, 0.001), and increased confidence when leaving home
(P, 0.05). The TDI measures of effort, task, and functional
impairment were uniformly improved (P, 0.001). The
EXAcerbations of Chronic Pulmonary Disease Tool (EXACT)–
PRO, dyspnea domain, was significantly improved in the Zephyr
Valve group. Improvements correlated with changes in residual
volume and residual volume/TLC ratio.
Conclusions: Patients with severe hyperinflated emphysema
achieving lung volume reductions with Zephyr Valves experience
improvements in multidimensional scores for breathlessness,
activity, and psychosocial parameters out to at least 12 months.
Clinical trial registered with www.clinicaltrials.gov (NCT01796392).
Keywords: chronic obstructive pulmonary disease; severe
emphysema; interventional bronchoscopy; patient-reported
outcomes; Zephyr Valve
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Breathlessness is a common and disabling
symptom in patients with chronic
obstructive pulmonary disease (COPD) (1)
and is defined as “a subjective experience of
breathing discomfort that consists of
qualitatively distinct sensations that vary in
intensity” as interpreted by the individual
(2). Progression of COPD is associated with
worsening breathlessness accompanied by a
downward spiral of symptom-induced
inactivity (3), muscle deconditioning and
weakness (4), and significant negative
impact on health-related quality of life and
survival (5–8).
The emphysema-hyperinflated
phenotype is characterized by a heightened
sense of dyspnea and exercise intolerance
caused by mechanical constraints imposed
on ventilation at rest and during activity (9).
The physiological model of patient-reported
shortness of breath in COPD presented by
Jolley andMoxham (10) describes the effects
of daily activities on increasing respiratory
muscle load-capacity imbalance, neural
respiratory drive, and neuromechanical
dissociation, which are magnified in
severe emphysema and hyperinflation.
Hyperinflation is a key contributor to an
individual’s perception of breathlessness
and to exercise limitation (11, 12), and is a
predictor not only of risk of exacerbation
(13) but of all-cause mortality (14, 15),
prompting targeted strategies to reduce
hyperinflation.
In selected individuals, lung volume
reduction surgery has been shown to
improve lung function, exercise capacity,
dyspnea, and quality of life, and to extend
survival (16, 17). However, only a small
number of patients with COPD are eligible
for lung volume reduction surgery,
periprocedural morbidity and mortality is
relatively high, and only a few hundred
procedures are performed annually in the
United States. Recent efforts have been
focused on the development of less invasive
approaches. Bronchoscopic lung volume
reduction using the Zephyr Endobronchial
Valve (Zephyr Valve; Pulmonx
Corporation) has been shown in multiple
randomized controlled trials (RCTs) to
reduce hyperinflation and to improve lung
function, exercise tolerance, dyspnea, and
overall quality of life in individuals with
heterogeneous (18–21) or homogeneous
(22) emphysema and little to no interlobar
collateral ventilation.
COPD is a multifaceted condition and
assessment of airflow limitation alone
does not adequately reflect the burden of
the disease. FEV1 has been shown to
correlate poorly with patient-reported
outcomes (PROs), including dyspnea,
activity, and health status (23, 24).
Furthermore, there is a significant disparity
between subjects’ perception of disease
severity and the degree of severity indicated
by a unidimensional breathlessness scale
(25), which may lead to undertreatment.
Therefore, to quantify symptoms, the most
efficient and objective way is to assess
symptom severity, activity limitation, and
psychosocial status using multidimensional
patient-centric measures (26). In doing so, a
better estimate of treatment effects may be
gained.
The LIBERATE (Lung Function
Improvement after Bronchoscopic Lung
Volume Reduction with Pulmonx
Endobronchial Valves used in Treatment of
Emphysema) study is the largest multicenter
prospective RCT of the Zephyr Valve in
patients with severe heterogeneous
emphysema, hyperinflation, and little to no
interlobar collateral ventilation assessed
using the Chartis System (Pulmonx Corp.).
Multiple patient-centric assessments were
included in the study to allow an in-depth
evaluation of the impact of reduced
hyperinflation on dyspnea and symptoms
that are most meaningful to patients
with COPD. Published PROs have so far
focused on the modified Medical Research
Council (mMRC) Dyspnea Scale and the
St. George’s Respiratory Questionnaire
(SGRQ) total score. The importance
of PROs in a comprehensive evaluation
of response to treatment is recognized
and recommended in recent guideline
updates (27).
We present the PROs of multidimensional
measures of 1) dyspnea, from the
Transitional Dyspnea Index (TDI), focal
score; the COPD Assessment Test (CAT;
breathlessness on hill/stairs); Borg; and the
EXAcerbations of Chronic Pulmonary
Disease Tool [EXACT]–PRO, dyspnea
domain; 2) activity, from the TDI, magnitude
of task/effort/functional impairment; CAT
(limited activities); and the SGRQ, activity
domain; and 3) psychosocial status, from
the SGRQ, impacts domain, and CAT
(confidence and energy) at 12 months after
their bronchoscopic lung volume reductions
with Zephyr Valves beyond the mMRC
Dyspnea Scale and the SGRQ, total score,
that were previously reported in the
LIBERATE trial (21). Evaluation of these
symptom metrics in this study population
before and after endobronchial valve
implantation has not been published.
Some of the results have previously
been reported in abstract form (28).
Methods
The LIBERATE study design
(NCT 01796392) has been published
A complete list of the LIBERATE Study Group may be found before the beginning of the REFERENCES.
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previously (21). The multicenter study
conducted under a U.S. Food and Drug
Administration–approved Investigational
Device Exemption for the Zephyr Valve was
approved by the respective institutional
review boards or ethics committees at each
site, and all participating subjects were
provided written informed consent. The
study protocol is summarized in the online
supplement.
Multiple discrete and validated
self-administered questionnaires were
completed at baseline and follow-up visits,
and have not been previously reported (see
Table E1 in the online supplement for
timing of each assessment). These included:
for dyspnea, the TDI, focal score; Borg scale
of perceived exertion; EXACT-PRO diary,
dyspnea domain; and the CAT question
regarding breathlessness on hill/stairs; for
activity, the TDI, magnitude of task,
magnitude of effort, and functional
impairment; the CAT questions regarding
limited activities; and the SGRQ, activity
domain; and, for psychosocial status, the
SGRQ, impacts domain, and the CAT
questions regarding confidence and energy.
Neither the study participants nor the
assessing physicians were blinded to the
randomization. At follow-up assessments,
study participants were not reminded of,
and thus were not aware of, their baseline
scores.
Study participants also maintained a
daily diary in which they noted adherence
with the pulmonary rehabilitation program,
completed the EXACT-PRO questionnaire,
and noted health status changes. The
following question was administered as part
of the daily diary: “Mark the scale to show
the intensity of the emphysema symptoms
you had today (scale of 0 = none to
10 = intolerable).” Although this question
was not validated, it asks a global question of
clinical interest using a visual analogue scale
of 0 to 10 for rating the subject’s perception
of emphysema symptom intensity every
day. Days that were better or worse were
determined by a follow-up score that was
above (worse) or below (better) the baseline
score.
Statistical Analysis
All data were collected prospectively;
however, inferential statistics for the SGRQ
domains, the TDI domains, the mMRC
Dyspnea Scale, CAT individual questions,
Borg, and EXACT-PROs were not
prospectively specified in the study protocol
and hence are considered post hoc. Statistical
analyses were performed using SAS version
9.3 (SAS Institute). Descriptive statistics
include means, standard deviations, and
95% confidence intervals. Change from
baseline to 12 months and the percentage of
subjects meeting a minimal clinically
important difference (MCID; or
“responder”) per group were reported using
an MCID of greater than or equal to 15%
increase for FEV1 (29), greater than or equal
to 25 m increase for 6-minute-walk distance
(6MWD) (30), greater than or equal to a
4-point reduction for the SGRQ (31), greater
than or equal to a 1-point increase for the
TDI (32), and greater than or equal to a
1-point reduction for mMRC Dyspnea Scale
(33) and Borg (34). Changes from baseline
were reported for EXACT-PRO, dyspnea
domain, and individual CAT (35) questions
only.
Missing data for the prospectively
defined primary and secondary endpoints
were imputed as baseline carried forward
for deaths, by linear interpolation for
intermittent missing values, by multiple
imputation methods for truncated missing
values. Cohen’s effect size was calculated as
the difference in means divided by pooled
standard deviation (referred to as Cohen’s D).
Continuous variables were compared
with the Wilcoxon rank sum (for
nonparametric data) or an analysis of
covariance with the respective baseline value
as the covariate (for parametric data), and
categorical variables were compared with
the Fisher exact test.
Scatter plots and Pearson correlation
coefficients were performed to assess the
relationships between hyperinflation
(residual volume [RV] and RV/TLC) and
dyspnea (EXACT-PRO), lung function
(FEV1), quality of life (the SGRQ, total
score), and exercise capacity (6MWD).
Statistical significance was determined at the
P, 0.05 level. Poisson regression adjusted
for each subject’s length of follow-up was
used to analyze daily diary data for days that
were better or worse from baseline.
Results
Subject Characteristics
A total of 190 patients with severe
heterogeneous emphysema and
hyperinflation with little or no collateral
ventilation in the target lobe were enrolled
with a 2 to 1 randomization (128 Zephyr
Valve and 62 standard of care [SoC]).
Baseline demographic and clinical
characteristics data have previously been
reported (21) and are provided for reference
in Table E2. Except for a higher proportion
of Global Initiative for Chronic Obstructive
Lung Disease stage IV subjects in the SoC
group, there were no differences between
groups for the other variables. Twelve
subjects did not complete the 12-month
assessments: 9 in the Zephyr Valve group
(2 withdrew consent, 2 withdrawn by
investigators, and 5 died) and 3 in the SoC
group (2 withdrawn by investigators and
1 died) (21).
Dyspnea Measures
Multiple measures of dyspnea showed
statistically significant improvements in the
Zephyr Valve group compared with SoC at
12 months (Table 1). The mean group
differences for the change from baseline to
12 months (D Zephyr Valve–SoC) were
20.8 points for mMRC Dyspnea Scale
(P, 0.001; previously reported [21]); 4.3
points for the TDI, focal score (P, 0.001);
20.9 points for Borg after the 6-minute-
walk test (P, 0.001); 28.8 points for the
EXACT-PRO, dyspnea domain (P= 0.002);
and 20.6 points for the CAT, dyspnea
question (P= 0.002).
The absolute changes from baseline to
12 months for the SGRQ domains, the TDI
domains, and the individual questions in
CAT are provided in Figures E1–E3.
Dyspnea Responders
As shown in Figure 1, significantly more
responders at 12 months were observed for
the Zephyr Valve compared with SoC group
patients for improvements in mMRC
Dyspnea Scale of greater than or equal to a
1-point decrease (48.2% vs. 19.0%,
respectively; P, 0.001) and for the TDI,
focal score, of greater than or equal to a
1-point increase (61.9% vs. 15.8%,
respectively; P, 0.001). Responders for
Borg dyspnea score after the 6-minute-walk
test favored the Zephyr Valve over SoC,
but this was not statistically significant
(>1-point decrease; 44.1% vs. 35.1%,
respectively; P= 0.321).
Activity Measures
Multiple measures of activity levels assessed
at 12 months showed statistically significant
improvements in the Zephyr Valve group
compared with SoC group (see Table 1). An
improvement in the 6MWD of 39.3 m in
ORIGINAL RESEARCH
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favor of the Zephyr Valve group was
reported previously (21).
Activity Responders
Significantly more responders at 12 months
were observed for the Zephyr Valve group
compared with SoC for 6MWD (previously
reported [21]; 41.8% vs. 19.6%, respectively;
P= 0.003), the TDI, magnitude of task
(60.5% vs. 13.8%, respectively; P, 0.001);
the TDI, magnitude of effort (58.3% vs.
15.5%, respectively; P, 0.001); the TDI,
functional impairment (57.9% vs. 15.5%,
respectively; P, 0.001); and the SGRQ,
activity domain (57.4% vs. 27.1%,
respectively; P, 0.001) (Figure 2).
Psychosocial Status
At 12 months, statistically significant
improvements for the Zephyr Valve group
over SoC group were demonstrated for
absolute changes from baseline to
12 months for the SGRQ, total score (27.1
points; P= 0.004; previously reported [21]);
the SGRQ, impact score (29.7 points;
P= 0.004); and CAT questions regarding
confidence (20.7 points; P= 0.024) and
energy (20.7 points; P= 0.014) (see Table 1).
There were significantly more SGRQ
responders at 12 months in the Zephyr Valve
group compared with SoC, with 56.2% versus
30.2%, respectively, using an MCID of 24
points (previously reported in Reference 21).
For the SGRQ, impacts domain, the
responder rates were 63.2% versus 42.4%
(Zephyr Valve vs. SoC, respectively; P=0.01)
using an MCID of 24 points.
Daily Diary Scores
Compared with SoC, the Zephyr Valve
group had significantly more days per year
when their emphysema symptom intensity
was better than baseline (>1-point
improvement) with 206 versus 102 days
(Zephyr Valve vs. SoC, respectively; P, 0.001;
Poisson regression adjusted for each subject’s
length of follow-up) and significantly fewer
days that were worse than baseline (>1-point
worsening) with 95 versus 122 days (Zephyr
Valve vs. SoC, respectively; P, 0.001).
Patients in the Zephyr Valve group
experienced the same degree of emphysema
symptom intensity as at baseline on fewer days
compared with the SoC patients (64 days vs.
141 days, Zephyr Valve vs. SoC, respectively;
P, 0.001). The weekly averages of the daily
































Figure 1. Responders based on minimal clinically important difference of greater than or equal to a
1-point decrease for the mMRC Dyspnea Scale and Borg after a 6MWT, and greater than or equal to a
1-point increase for the TDI, focal score, from baseline to 12 months. Dark blue bars represent the
Zephyr Valve group and the light blue bars represent the SoC group. 6MWT=6-minute-walk test;







































Figure 2. Responders based on minimal clinically important difference of greater than or equal to a 25 m increase for 6MWD, greater than or
equal to a 1-point increase for the TDI domain scores (magnitude of task, magnitude of effort, and functional impairment), and greater than or equal
to a 4-point decrease for the SGRQ, activity domain. Dark blue bars represent the Zephyr Valve group and the light blue bars represent the SoC group.
6MWD=6-minute-walk distance; SGRQ=St. George’s Respiratory Questionnaire; SoC= standard of care; TDI = Transitional Dyspnea Index.
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symptom intensity over the 12 months is
shown in Figure 3.
As shown in Table 1, the calculated
effect size for all parameters assessed ranged
from 0.38 to 0.89 and in all cases were
greater than the Cohen’s D of 0.2, which
represents a small effect size.
Relationships between Reduction in
Hyperinflation and Effectiveness
Assessed Using PRO Measures
Clinically meaningful improvement in static
hyperinflation at 12 months favoring the
Zephyr Valve group has been reported (21).
Figure 4 shows that reductions in RV (L) and
RV/TLC are significantly correlated with
improvements in FEV1; 6MWD; the SGRQ,
total score; and dyspnea (EXACT-PRO).
Discussion
This post hoc analysis of data from the
LIBERATE multicenter RCT demonstrated
statistically significant and clinically
meaningful improvements in multiple
patient-reported measures of dyspnea,
activity, and psychosocial status favoring the
Zephyr Valve over SoC at 12 months. The
findings of this study expand on the results of
RCTs evaluating the Zephyr Valve that have
previously demonstrated physiological
benefits and improvements in several
measures of health-related quality of life,
principally using the mMRC Dyspnea Scale
and the SGRQ (18–22, 36). It is also
consistent with a meta-analysis that
demonstrated a correlation between lung
volume reduction and clinical benefit (37). Of
particular significance is the finding that the
effect size based on Cohen’s D is moderate to
large for each of the parameter assessed.
Dyspnea is usually the most burdensome
symptom in patients with COPD and is
frequently multifactorial in origin (38).
Hyperinflation is a key factor driving
exertional dyspnea in an individual with
advanced emphysema (11). Multiple PROs
demonstrated statistically significant
improvements in the Zephyr Valve group
compared with SoC at 12 months, notably the
TDI, focal score, and the EXACT-PRO,
dyspnea domain. The TDI demonstrates a
high correlation between dyspnea and stage of
disease severity (39), and measures aspects of
daily living as they relate to the amount of
breathlessness experienced (40). The EXACT-
PRO offers a validated daily diary–based
symptom assessment that helps to better
characterize exacerbations (41) and reduce the
recall bias affecting 60% of events that go
unreported (42). Use of these questionnaires
complement the information obtained from
lung function measurements, helping to
provide a more consistent description of an
individual’s sensation of breathlessness in
response to lung volume reduction treatment.
Most patients with COPD are relatively
inactive, spending significantly less time
standing and walking than persons without
COPD (43). Dyspnea is the principal
symptom limiting exercise in patients with
advanced COPD, leading to activity
avoidance (3, 43–45). It is important to
break this cycle because reduced physical
activity is a predictor of future risk of
exacerbation, hospitalization, and early
mortality (46, 47). Multiple measures of
activity levels in patients treated with
Zephyr Valves showed statistically
significant improvements compared with
SoC at 12 months, notably the TDI
measures of effort, task, and functional
impairment. These changes in activity levels
can be very meaningful for patients. For
example, a 3-point change in the TDI, focal
score, implies a return to most work/leisure
activities previously impacted, and 54.9% of
patients treated with Zephyr Valve achieved
this in LIBERATE.
The impact of COPD is not limited to the
physical restrictions levied on the lifestyle of
the patient. The experience of breathlessness
“derives from interactions among multiple
physiological psychological, social, and
environmental factors, and may induce
secondary physiological and behavioural
responses” (2). Breathlessness is associated
with panic, anxiety, and depression (48). The
inability to engage in activities of daily living
can be one of the most distressing symptoms
for patients with COPD. The opportunity to
improve quality of life and permit resumption,
even in part, of familiar activities is highly
desirable (49). Our findings show that patients
using the Zephyr Valve had improvements in
psychosocial status, demonstrated by
statistically significant improvements for
patients using the Zephyr Valve over SoC in
the SGRQ, impacts domain, and in CAT







































Figure 3. Emphysema symptom intensity presented as weekly averages of the daily change from baseline values up to 12 months for the Zephyr
Valve (blue closed squares) versus SoC (blue open squares) groups. SoC= standard of care.
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Pearson Correlation Coefficient: –0.690
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p-value: <.001
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p-value: <.001
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Pearson Correlation Coefficient: 0.406
R-square: 0.165
p-value: <.001
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Pearson Correlation Coefficient: 0.468
R-square: 0.219
p-value: <.001
Change from Baseline at Year 1 in RV/TLC Ratio
–0.4 –0.3 –0.2 0.0–0.1
EBV (n = 111)





































































Pearson Correlation Coefficient: 0.407
R-square: 0.166
p-value: <.001
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Pearson Correlation Coefficient: 0.457
R-square: 0.209
p-value: <.001
Change from Baseline at Year 1 in RV/TLC
-0.4 -0.3 -0.2 -0.1 0.0
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Figure 4. Correlation between reduction in hyperinflation (RV) and RV/TLC ratio, and changes from baseline to 12 months, for postbronchodilator FEV1;
6MWD; the SGRQ; and EXACT-PRO, dyspnea domain. Data are for the Zephyr Valve group. 6MWD=6-minute-walk distance; BD=bronchodilator;
EBV=Zephyr endobronchial valve; EXACT-PRO=EXAcerbations of Chronic pulmonary disease Tool–Patient-Reported Outcome; FEV1 = forced expiratory
volume in 1 second; RV= residual volume; SGRQ=St. George’s Respiratory Questionnaire; TLC= total lung capacity.
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Patients frequently report good and bad
days with significant fluctuations over time
(50–53). The quantitative improvement in all
three aspects of breathlessness, activity levels,
and psychosocial well-being measured at
specified time points is also reflected in the
daily diary assessment of patients, with those
using the Zephyr Valve experiencing
significantly more days that were better and
fewer days that were worse over 12 months.
The improvements in multidimensional
PROs were correlated with reduction in
hyperinflation and elaborate on the clinical
benefits observed in individuals undergoing
this treatment (37). Utilization of
varied multidimensional questionnaires
and of a daily diary assessment tool, as
demonstrated in this study, afford a more
comprehensive evaluation of the impact of
the Zephyr Valve that is personalized to the
symptoms of the individual and supports a
phenotype-based management strategy as
advocated by the Global Initiative for
Chronic Obstructive Lung Disease
guidelines (38). These data add to the
growing evidence base for the Zephyr
Valve accomplishing and maintaining
improvements that are not limited to lung
function and objective exercise assessment
but, importantly, to disease-specific
symptoms and health-related quality of life,
which permits patients the ability to
reengage in their activities of daily living.
The strengths of the study include the use
of standardized, validated, disease-specific,
treatment-responsive instruments such as the
SGRQ, CAT, and the TDI that provide a
complement and refinement to previously
published physiological data that is meaningful
to the individual, and which is crucial to guide
therapeutic management. Moreover, a daily
diary assessment adds greater detail and
context to what is a variable tapestry of
symptoms from day to day. Furthermore, they
provide an easy and cost-efficient way for
acquiring data to characterize complex issues
such as breathlessness and health-related
quality of life in COPD that cannot be achieved
by any one physiological correlate (26). Lastly,
the presence of a SoC group out to 12 months
affords more accurate measurement of the
impact of the Zephyr Valve on these
multidimensional metrics. Limitations of the
study include the use of these qualitative tools
that can be subject to recall bias (54) and could
be further confounded due to the lack of
blinding. Neither the study participants nor
the assessing physicians were blinded to the
randomization, which could introduce bias
for self-reported outcomes. However, the
strong correlation between reduction in
hyperinflation as assessed by a reduction in
RV and RV/TLC ratio, both of which are
objective measures, and the changes from
baseline to 12months for postbronchodilator
FEV1; 6MWD; the SGRQ score; and the
EXACT-PRO, dyspnea domain, suggest that
the results are robust. It should also be noted
that the number of patients who did not
complete the 12-month assessments was
greater in those randomized to Zephyr
Valves than in the SoC group, which could
have biased the results toward benefit.
Finally, a select group of patients with severe
emphysema and hyperinflation with little or
no collateral ventilation was treated, and the
results cannot be generalized to other grades
of airflow limitation.
Conclusions
Post hoc analysis of data from the LIBERATE
study demonstrate that patients with severe
emphysema and hyperinflation who achieve
lung volume reductions following treatment
with Zephyr Valves experience moderate to
large improvements in multidimensional scores
for breathlessness, activity, and psychosocial
parameters that may permit reengagement in
activities of daily living out to at least 12
months. The interruption of the downward
spiral of symptom-induced inactivity, muscle
deconditioning, and ensuing weakness allows
patients to experience improved activity, feeling
of well-being, more confidence, and a better
quality of life. These results supplement the
findings of published randomized controlled
studies in patients with heterogeneous (18–21)
and those with homogeneous (22) emphysema,
in whom accompanying improvements in lung
function, exercise capacity, dyspnea, and
overall quality of life have consistently been
shown. n
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